Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER versus PREMASOL 10 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER versus PREMASOL 10 IN PLASTIC CONTAINER.
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER vs PREMASOL 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosin II 4.25% in Dextrose 25% provides essential amino acids and dextrose for parenteral nutrition. Amino acids serve as building blocks for protein synthesis, while dextrose supplies a source of calories to prevent catabolism. The combination aims to maintain nitrogen balance and support metabolic functions.
Provides essential amino acids for protein synthesis and maintenance of nitrogen balance.
Administer as a continuous intravenous infusion. Typical adult dose: 1.0-1.5 g amino acids/kg/day (equivalent to approximately 23-35 mL/kg/day of AMINOSYN II 4.25% in DEXTROSE 25%) via central venous line. Adjust based on metabolic needs and tolerance.
1-2 g/kg/day intravenously as a continuous infusion or in divided doses; typical starting dose for adults with normal renal function: 1 g/kg/day.
None Documented
None Documented
Amino acids: 0.5-2 hours; dextrose: 1-4 hours in non-diabetic patients; context: reflects rapid uptake and metabolism
The terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for most amino acids, reflecting rapid metabolism and distribution. Clinically, this supports continuous infusion to maintain plasma amino acid levels.
Renal: >90% as amino acids and metabolites; biliary/fecal: minimal (<2%)
Amino acids in Premasol 10% are metabolized and the nitrogen is eliminated primarily as urea via renal excretion (80-90%). A small fraction is excreted in feces (5-10%) and as ammonia in urine. Biliary excretion is negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution